0IGA.LSE

Emergent Biosolutions Inc.

0IGA.LSE, UK

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

https://www.emergentbiosolutions.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
0IGA.LSE
stock
0IGA.LSE

Binghatti’s $500m sukuk debuts on London Stock Exchange TradeArabia

Read more →
0IGA.LSE
stock
0IGA.LSE

Get International Airlines (IAG) Live Prices London South East

Read more →

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.05

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

1.34

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.79 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

3.50 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2.47 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.51

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Emergent Biosolutions Inc.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.11

Latest Release

Date

2025-09-30

EPS Actual

0.9062

EPS Estimate

0.11

EPS Difference

0.7962

Surprise Percent

723.8182%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5.5)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.